OCS OCULIS HOLDING AG

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors.

Attachment



EN
18/11/2025

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces European Medicines Agency PRIME Designation for Privo...

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual outcomes, significantly affecting function and quality of life Decision supported by positive Phase 2 ACUITY data showing substantial improvements in vision combined ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Announces European Medicines Agency PRIME Designation for Privo...

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative long-term visual outcomes, significantly affecting function and quality of life Decision supported by positive Phase 2 ACUITY data showing substantial improvements in vision combined with anatomical and biological neuroprotective benefits...

March 31, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Publishes Notifications of Transactions by Persons Discharging ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities ZUG, Switzerland, March 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to annual equity incentive awards granted to a member of the executive committee of the Company. Attachment

March 27, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Present at Upcoming North American Neuro-Ophthalmology Socie...

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. This premier annual gathering of neuro‑ophthalmology experts worldwide provides a scien...

March 16, 2026 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Present at Upcoming North American Neuro-Ophthalmology Socie...

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting. This premier annual gathering of neuro-ophthalmology experts worldwide provides a scientific forefront pla...

March 16, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch